Proactive Investors - Run By Investors For Investors

AstraZeneca gets US boost for bladder cancer drug

Drug group gets "breakthrough therapy" designation for durvalumab in the US
AstraZeneca gets US boost for bladder cancer drug
AstraZeneca is said to have received three "breakthrough therapy" designations for cancer drugs

Shares in drug group AstraZeneca (LON:AZN) were healthier after it received a US boost for a bladder cancer treatment.

The stock rose 70.5p, or nearly 1.7%, to 4254.5p as the Food & Drug Administration (FDA) designated its durvalumab drug as a "breakthrough therapy".

Breakthrough therapy designation (BTD) is designed to speed up development of drugs for serious conditions which have shown encouraging early clinical results, improvements over existing treatments or potential to address significant unmet medical need.

AstraZeneca's senior vice-president and head of immuno-oncology in global medicines development, Robert Iannone, said: "Metastatic bladder cancer is an area of enormous unmet medical need.

"We are encouraged by this breakthrough therapy designation. We look forward to working closely with the FDA to bring durvalumab to bladder cancer patients as soon as possible."

The designation, based on early clinical data from a phase one trial in patients with advanced urothelial bladder cancer, is said to be the third BTD that AstraZeneca has received for an oncology medicine.


Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Related Articles

April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.